Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Jul 5

PMID 34222013

Citations 6

Authors

Junxia Hu

Xin Wang

Fei Chen

Mengjie Ding

Meng Dong

Wanqiu Yang

Meifeng Yin

Jingjing Wu

Lei Zhang

Xiaorui Fu

Zhenchang Sun

Ling Li

Xinhua Wang

Xin Li

Shuangshuang Guo

Dianbao Zhang

Xiaohui Lu

Qing Leng

Mingzhi Zhang

Linan Zhu

Xudong Zhang

Qingjiang Chen

Affiliations

Soon will be listed here.

Abstract

Objective: The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (R/R-DLBCL) after second-line treatment failure is extremely poor. This study prospectively observed the efficacy and safety of decitabine with a modified cisplatin, cytarabine, and dexamethasone (DHAP) regimen in R/R-DLBCL patients who failed second-line treatment.

Methods: Twenty-one R/R-DLBCL patients were enrolled and treated with decitabine and a modified DHAP regimen. The primary endpoints were overall response rate (ORR) and safety. The secondary endpoints were progression-free survival (PFS) and overall survival (OS).

Results: ORR reached 50% (complete response rate, 35%), five patients (25%) had stable disease (SD) with disease control rate (DCR) of 75%. Subgroup analysis revealed patients over fifty years old had a higher complete response rate compared to younger patients ( = 0.005), and relapsed patients had a better complete response rate than refractory patients ( = 0.031). Median PFS was 7 months (95% confidence interval, 5.1-8.9 months). Median OS was not achieved. One-year OS was 59.0% (95% CI, 35.5%-82.5%), and two-year OS was 51.6% (95% confidence interval, 26.9%-76.3%). The main adverse events (AEs) were grade 3/4 hematologic toxicities such as neutropenia (90%), anemia (50%), and thrombocytopenia (70%). Other main non-hematologic AEs were grade 1/2 nausea/vomiting (40%) and infection (50%). No renal toxicity or treatment-related death occurred.

Conclusion: Decitabine with a modified DHAP regimen can improve the treatment response and prognosis of R/R-DLBCL patients with good tolerance to AEs, suggesting this regimen has potential as a possible new treatment option for R/R-DLBCL patients after second-line treatment failure.

Clinical Trial Registration: ClinicalTrials.gov, identifier: NCT03579082.

Citing Articles

Progress Toward Epigenetic Targeted Therapies for Childhood Cancer.

Liapodimitri A, Tetens A, Craig-Schwartz J, Lunsford K, Skalitzky K, Koldobskiy M Cancers (Basel). 2025; 16(24.

PMID: 39766049 PMC: 11674401. DOI: 10.3390/cancers16244149.

Targeted chitosan nanobubbles as a strategy to down-regulate microRNA-17 into B-cell lymphoma models.

Capolla S, Argenziano M, Bozzer S, DAgaro T, Bittolo T, De Leo L Front Immunol. 2023; 14:1200310.

PMID: 37359561 PMC: 10285521. DOI: 10.3389/fimmu.2023.1200310.

Influence of corticosteroid treatment on CXCR4 expression in DLBCL.

Martin S, Viertl D, Janz A, Habringer S, Keller U, Schottelius M EJNMMI Res. 2023; 13(1):40.

PMID: 37162652 PMC: 10172459. DOI: 10.1186/s13550-023-00993-4.

Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis.

Kim J, Cho J, Yoon S, Kim W, Kim S Cancer Res Treat. 2023; 55(3):1031-1047.

PMID: 36915243 PMC: 10372592. DOI: 10.4143/crt.2022.1658.

Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool.

Kalinkova L, Sevcikova A, Stevurkova V, Fridrichova I, Ciernikova S Int J Mol Sci. 2023; 24(1).

PMID: 36614080 PMC: 9820560. DOI: 10.3390/ijms24010633.

References

Crump M, Neelapu S, Farooq U, Van den Neste E, Kuruvilla J, Westin J . Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808. PMC: 5649550. DOI: 10.1182/blood-2017-03-769620. View

Qin T, Youssef E, Jelinek J, Chen R, Yang A, Garcia-Manero G . Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res. 2007; 13(14):4225-32. DOI: 10.1158/1078-0432.CCR-06-2762. View

Lisenko K, McClanahan F, Schoning T, Schwarzbich M, Cremer M, Dittrich T . Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma. BMC Cancer. 2016; 16:267. PMC: 4828891. DOI: 10.1186/s12885-016-2289-y. View

Benton C, Thomas D, Yang H, Ravandi F, Rytting M, OBrien S . Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014; 167(3):356-65. PMC: 4198465. DOI: 10.1111/bjh.13050. View

Chau I, Webb A, Cunningham D, Hill M, Rao S, Ageli S . An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. Br J Haematol. 2002; 115(4):786-92. DOI: 10.1046/j.1365-2141.2001.03181.x. View

Burke M, Lamba J, Pounds S, Cao X, Ghodke-Puranik Y, Lindgren B . A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2014; 89(9):889-95. PMC: 4134715. DOI: 10.1002/ajh.23778. View

Liu L, Chen L, Wu X, Li X, Song Y, Mei Q . Low-dose DNA-demethylating agent enhances the chemosensitivity of cancer cells by targeting cancer stem cells via the upregulation of microRNA-497. J Cancer Res Clin Oncol. 2016; 142(7):1431-9. DOI: 10.1007/s00432-016-2157-9. View

Cheson B, Pfistner B, Juweid M, Gascoyne R, Specht L, Horning S . Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5):579-86. DOI: 10.1200/JCO.2006.09.2403. View

Witzig T, Geyer S, Kurtin P, Colgan J, Inwards D, Micallef I . Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Leuk Lymphoma. 2008; 49(6):1074-80. PMC: 3905358. DOI: 10.1080/10428190801993470. View

10.

Juergens R, Wrangle J, Vendetti F, Murphy S, Zhao M, Coleman B . Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2012; 1(7):598-607. PMC: 3353724. DOI: 10.1158/2159-8290.CD-11-0214. View

11.

Li S, Xue L, Wang M, Qiang P, Xu H, Zhang X . Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma. Onco Targets Ther. 2019; 12:5627-5638. PMC: 6635897. DOI: 10.2147/OTT.S198567. View

12.

Nagle S, Woo K, Schuster S, Nasta S, Stadtmauer E, Mick R . Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. Am J Hematol. 2013; 88(10):890-4. DOI: 10.1002/ajh.23524. View

13.

Lu B, Thanawala S, Zochowski K, Burke M, Carroll W, Bhatla T . Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples. Leuk Lymphoma. 2016; 57(8):1938-41. DOI: 10.3109/10428194.2015.1110747. View

14.

Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y . Epigenetic resensitization to platinum in ovarian cancer. Cancer Res. 2012; 72(9):2197-205. PMC: 3700422. DOI: 10.1158/0008-5472.CAN-11-3909. View

15.

Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L . Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma. J Clin Oncol. 2019; 37(17):1479-1489. DOI: 10.1200/JCO.18.02151. View

16.

Kalac M, Scotto L, Marchi E, Amengual J, Seshan V, Bhagat G . HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood. 2011; 118(20):5506-16. PMC: 3217353. DOI: 10.1182/blood-2011-02-336891. View

17.

Khandelwal M, Anand V, Appunni S, Seth A, Singh P, Mathur S . Decitabine augments cytotoxicity of cisplatin and doxorubicin to bladder cancer cells by activating hippo pathway through RASSF1A. Mol Cell Biochem. 2018; 446(1-2):105-114. DOI: 10.1007/s11010-018-3278-z. View

18.

Abdou A, Asaad N, Kandil M, Shabaan M, Shams A . Significance of stromal-1 and stromal-2 signatures and biologic prognostic model in diffuse large B-cell lymphoma. Cancer Biol Med. 2017; 14(2):151-161. PMC: 5444927. DOI: 10.20892/j.issn.2095-3941.2017.0007. View

19.

Elstrom R, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R . Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin Lymphoma Myeloma Leuk. 2010; 10(3):192-6. DOI: 10.3816/CLML.2010.n.030. View

20.

Coiffier B, Sarkozy C . Diffuse large B-cell lymphoma: R-CHOP failure-what to do?. Hematology Am Soc Hematol Educ Program. 2016; 2016(1):366-378. PMC: 6142522. DOI: 10.1182/asheducation-2016.1.366. View